The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far

Research output: Contribution to journalArticle

Standard

The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far. / Heynickx, Nathalie; Herrmann, Ken; Vermeulen, Koen; Baatout, Sarah; Aerts, An.

In: Nuclear Medicine and Biology, Vol. 98-99, 2021, p. 30-39.

Research output: Contribution to journalArticle

Bibtex - Download

@article{1a78e2c124ef4f8ea4415fae65de7b31,
title = "The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far",
abstract = "At present, prostate cancer remains the second most occurring cancer in men, in Europe. Treatment efficacy for therapy of advanced metastatic disease, and metastatic castration-resistant prostate cancer in particular is limited. Prostate-specific membrane antigen (PSMA) is a promising therapeutic target in prostate cancer, seeing the high amount of overexpression on prostate cancer cells. Clinical investigation of PSMA-targeted radionuclide therapy has shown good clinical efficacy. However, adverse effects are observed of which salivary gland hypofunction and xerostomia are among the most prominent. Salivary gland toxicity is currently the dose-limiting side effect for PSMA-targeted radionuclide therapy, and more specifically for PSMA-targeted alpha therapy. To date, mechanisms underlying the salivary gland uptake of PSMA-targeting compounds and the subsequent damage to the salivary glands remain largely unknown. Furthermore, preventive strategies for salivary gland uptake or strategies for treatment of salivary gland toxicity are needed. This review focuses on the current knowledge on uptake mechanisms of PSMA-targeting compounds in the salivary glands and the research performed to investigate different strategies to prevent or treat salivary gland toxicity.",
keywords = "Prostate cancer, PSMA-targeted radionuclide therapy, Salivary gland toxicity, Xerostomia",
author = "Nathalie Heynickx and Ken Herrmann and Koen Vermeulen and Sarah Baatout and An Aerts",
note = "Score=10",
year = "2021",
doi = "10.1016/j.nucmedbio.2021.04.003",
language = "English",
volume = "98-99",
pages = "30--39",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier",

}

RIS - Download

TY - JOUR

T1 - The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far

AU - Heynickx, Nathalie

AU - Herrmann, Ken

AU - Vermeulen, Koen

AU - Baatout, Sarah

AU - Aerts, An

N1 - Score=10

PY - 2021

Y1 - 2021

N2 - At present, prostate cancer remains the second most occurring cancer in men, in Europe. Treatment efficacy for therapy of advanced metastatic disease, and metastatic castration-resistant prostate cancer in particular is limited. Prostate-specific membrane antigen (PSMA) is a promising therapeutic target in prostate cancer, seeing the high amount of overexpression on prostate cancer cells. Clinical investigation of PSMA-targeted radionuclide therapy has shown good clinical efficacy. However, adverse effects are observed of which salivary gland hypofunction and xerostomia are among the most prominent. Salivary gland toxicity is currently the dose-limiting side effect for PSMA-targeted radionuclide therapy, and more specifically for PSMA-targeted alpha therapy. To date, mechanisms underlying the salivary gland uptake of PSMA-targeting compounds and the subsequent damage to the salivary glands remain largely unknown. Furthermore, preventive strategies for salivary gland uptake or strategies for treatment of salivary gland toxicity are needed. This review focuses on the current knowledge on uptake mechanisms of PSMA-targeting compounds in the salivary glands and the research performed to investigate different strategies to prevent or treat salivary gland toxicity.

AB - At present, prostate cancer remains the second most occurring cancer in men, in Europe. Treatment efficacy for therapy of advanced metastatic disease, and metastatic castration-resistant prostate cancer in particular is limited. Prostate-specific membrane antigen (PSMA) is a promising therapeutic target in prostate cancer, seeing the high amount of overexpression on prostate cancer cells. Clinical investigation of PSMA-targeted radionuclide therapy has shown good clinical efficacy. However, adverse effects are observed of which salivary gland hypofunction and xerostomia are among the most prominent. Salivary gland toxicity is currently the dose-limiting side effect for PSMA-targeted radionuclide therapy, and more specifically for PSMA-targeted alpha therapy. To date, mechanisms underlying the salivary gland uptake of PSMA-targeting compounds and the subsequent damage to the salivary glands remain largely unknown. Furthermore, preventive strategies for salivary gland uptake or strategies for treatment of salivary gland toxicity are needed. This review focuses on the current knowledge on uptake mechanisms of PSMA-targeting compounds in the salivary glands and the research performed to investigate different strategies to prevent or treat salivary gland toxicity.

KW - Prostate cancer

KW - PSMA-targeted radionuclide therapy

KW - Salivary gland toxicity

KW - Xerostomia

UR - https://ecm.sckcen.be/OTCS/llisapi.dll/overview/43875932

U2 - 10.1016/j.nucmedbio.2021.04.003

DO - 10.1016/j.nucmedbio.2021.04.003

M3 - Article

VL - 98-99

SP - 30

EP - 39

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

ER -

ID: 7126162